PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global biosimulation technology-enabled drug development company, in partnership with The University of Manchester, successfully organized the first-ever Health Care Summit on Model-based Precision Dosing on May 19-20 in the UK. Precision dosing is a key and proactive step toward achieving the goals of precision medicine, a global objective supported by world leaders, including President Obama under the Precision Medicine Initiative.
“Through its modeling and simulation work, Certara has been working toward the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient,” said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. “Through this Summit and the 15 examples which were presented that showcased the successful use of modeling and simulation in the hospital research environment, we are confident that precision dosing in healthcare will become mainstream shortly.”
Professor Kay Marshall, head of the Manchester Pharmacy School and a speaker at the conference, said: “Everyone is different and this means that they react to drugs in different ways. The emerging precision dosing field harnesses the explosion of genomic data and various markers of bodily functions using mathematical modeling to ensure that individuals get the best possible treatment.”
Speakers from eight countries, representing research institutions, academia, pharmaceutical companies, former regulators, and legal authorities spoke at the Summit. Sessions were organized around special populations representing the most fragile and complex population cohorts, including oncology, HIV, pediatric, obese, renally-impaired, cell transplant, and adolescent psychiatric patients and pregnant women. In addition to demonstrating how modeling and simulation facilitated individualized dosing, the conference focused on linking personalized dosing and its impact on public health.
Certara Chief Scientific Officer Amin Rostami, who also serves as the chair of systems pharmacology at The University of Manchester, said, “We now understand more fully the sources of variability, the individual characteristics of each patient, which can drive dosing decisions. The successful case studies shared at this Summit demonstrate that we are now ready to take the next step toward individualized dosing in everyday health care.”
Certara is a global biosimulation and regulatory writing company, committed to optimizing drug development decisions. Its clients include hundreds of international biopharmaceutical companies, leading academic institutions, and key regulatory agencies. Certara’s solutions, which span drug discovery through patient care, increase the probability of regulatory and commercial success by using the most scientifically-advanced modeling and simulation technologies and regulatory strategies. For more information, visit www.certara.com.